AI isn’t close to curing cancer. This startup says it knows what it will take.

TechCrunch · 1 week ago · 45

Vivodyne, a biotech startup, argues that AI drug-discovery models lack causal biological data from human tissue and built HIVE robotic labs to generate it autonomously. The company has raised under $80 million, opened a facility near San Francisco achieving twice the throughput of all US animal trials, and claims its tissues match human organ behavior at 94-100% accuracy depending on tissue type. Better human tissue data could improve AI models' ability to predict drug efficacy before costly clinical trials, where 90% of animal-tested drugs currently fail to gain regulatory approval.